Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takashi Seto

Showing results (11-20 of 242) with videos related to

Pageof 25
Sort By:
Oncotargets and Therapy|September 4, 2018
Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to dateTakaki Akamine, Gouji Toyokawa, Tetsuzo Tagawa, et al.
Anticancer Research|October 23, 2009
Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancerRiichiroh Maruyama, Hiroshi Wataya, Takashi Seto, et al.
Pediatrics International : Official Journal of the Japan Pediatric Society|April 9, 2022
Plerixafor stem cell mobilization in Japanese children: A post-marketing studyHiroaki Goto, Rie Kanamori, Satoshi Nishina, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 12, 2018
Is prophylactic cranial irradiation (PCI) needed in patients with extensive-stage small cell lung cancer showing complete response to first-line chemotherapy?Kaname Nosaki, Takashi Seto, Mototsugu Shimokawa, et al.
Thoracic Cancer|March 9, 2018
Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4-ALK fusion geneTakuro Kometani, Kenji Sugio, Atsushi Osoegawa, et al.
Annals of Thoracic and Cardiovascular Surgery : Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia|October 24, 2007
A long-term survivor after aggressive treatment for tracheal adenoid cystic carcinoma: a case reportRyuichi Suemitsu, Tatsuro Okamoto, Riichiroh Maruyama, et al.
Therapeutics and Clinical Risk Management|February 6, 2020
Rapidly Destructive Coxarthrosis as a Potential Side Effect of Crizotinib in a Patient with <i>ROS1</i>-Positive Lung AdenocarcinomaShinkichi Takamori, Takashi Seto, Mikako Jinnouchi, et al.
Annals of Thoracic and Cardiovascular Surgery : Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia|August 21, 2015
Prognostic Factors for Survival after Resection of Pulmonary Metastases from Colorectal CarcinomaAtsushi Osoegawa, Takuro Kometani, Seiichi Fukuyama, et al.
International Journal of Clinical Oncology|June 20, 2022
Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405)Naoki Haratake, Mototsugu Shimokawa, Takashi Seto, et al.
Drugs - Real World Outcomes|August 29, 2021
Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance StudyNobuhiro Tsukada, Momoko Nishikori, Hiroaki Goto, et al.
Pageof 25

Showing results (11-20 of 242) with videos related to

Sort By:
Pageof 25
Oncotargets and Therapy|September 4, 2018
Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to dateTakaki Akamine, Gouji Toyokawa, Tetsuzo Tagawa, et al.
Anticancer Research|October 23, 2009
Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancerRiichiroh Maruyama, Hiroshi Wataya, Takashi Seto, et al.
Pediatrics International : Official Journal of the Japan Pediatric Society|April 9, 2022
Plerixafor stem cell mobilization in Japanese children: A post-marketing studyHiroaki Goto, Rie Kanamori, Satoshi Nishina, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 12, 2018
Is prophylactic cranial irradiation (PCI) needed in patients with extensive-stage small cell lung cancer showing complete response to first-line chemotherapy?Kaname Nosaki, Takashi Seto, Mototsugu Shimokawa, et al.
Thoracic Cancer|March 9, 2018
Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4-ALK fusion geneTakuro Kometani, Kenji Sugio, Atsushi Osoegawa, et al.
Annals of Thoracic and Cardiovascular Surgery : Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia|October 24, 2007
A long-term survivor after aggressive treatment for tracheal adenoid cystic carcinoma: a case reportRyuichi Suemitsu, Tatsuro Okamoto, Riichiroh Maruyama, et al.
Therapeutics and Clinical Risk Management|February 6, 2020
Rapidly Destructive Coxarthrosis as a Potential Side Effect of Crizotinib in a Patient with <i>ROS1</i>-Positive Lung AdenocarcinomaShinkichi Takamori, Takashi Seto, Mikako Jinnouchi, et al.
Annals of Thoracic and Cardiovascular Surgery : Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia|August 21, 2015
Prognostic Factors for Survival after Resection of Pulmonary Metastases from Colorectal CarcinomaAtsushi Osoegawa, Takuro Kometani, Seiichi Fukuyama, et al.
International Journal of Clinical Oncology|June 20, 2022
Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405)Naoki Haratake, Mototsugu Shimokawa, Takashi Seto, et al.
Drugs - Real World Outcomes|August 29, 2021
Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance StudyNobuhiro Tsukada, Momoko Nishikori, Hiroaki Goto, et al.
Pageof 25